A study of levels of oxidative protein modification markers AOPP and IMA with risk factors of metabolic syndrome

Objective: the study was designed to look in if there was any role for protein oxidation markers [like Advanced Oxidation Protein Products (AOPP) and Ischemia Modified Albumin (IMA)] in the pathogenesis of metabolic syndrome (MetS) and effect of number of risk factors of MetS on the level of these protein oxidation markers.

Method: A total of 165 (n) patients were included in the study. Patients were divided into four groups based on presence or absence of 5 cardiovascular risk factors specified in revised NCEP (rNCEP) definition for MetS. Comparisons of the examined groups were statistically analysed by the application of Studentsttest. Analysis of variance (ANOVA) followed by multiple comparison post hoc Fisher test were used for the analysis of differences between the groups with different numbers of risk factors of MetS.

Results: Both AOPP and IMA values significantly correlated with waist circumference, glucose, HDL-Ch and TG (p value < 0.05). AOPP and IMA values between control group and the rest of the groups showed significant difference (p value <0.05). Systolic BP however, did not show significant association with AOPP as well as with IMA (p values 0.139 and 0.083 respectively).

Conclusion: On the basis of the findings from the present study, it may be concluded that oxidative protein modification markers, both AOPP and IMA are increased in metabolic syndrome. In addition, increased AOPP and IMA even prior to the development of MetS, may be used to prevent the development of MetS. However, it requires confirmation by further studies.

Oxidative protein modification, Advanced Oxidative Protein Products, Ischemia Modified Albumin, metabolic syndrome

Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report. 2009 May 5(13):1-7.

Ramachandran A, Snehalatha C, Latha E, Satyavani K, Vijay V. Clustering of cardiovascular risk factors in urban Asian Indians. Diabetes Care. 1998 Jun;21(6):967-71.

Hopps E, Noto D, Caimi G, Averna MR. A novel component of the metabolic syndrome: the oxidative stress. Nutr Metab Cardiovasc Dis. 2009 Jan;20(1):72-7.

Adults EPoDEaToHBCi, Guideline. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97.

Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004 Jan 27;109(3):433-8.

Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annual review of medicine. 1993;44(1):121-31.

Case J, Ingram DA, Haneline LS. Oxidative stress impairs endothelial progenitor cell function. Antioxid Redox Signal. 2008 Nov;10(11):1895-907.

Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart. 2006 Jan;92(1):113-4.

Grzebyk E, Piwowar A. [Glycoxidative modification of albumin in medical research]. Pol Merkur Lekarski. 2013 Apr;34(202):239-42.

Atabek ME, Keskin M, Yazici C, Kendirci M, Hatipoglu N, Koklu E, et al. Protein oxidation in obesity and insulin resistance. Eur J Pediatr. 2006 Nov;165(11):753-6.

Piwowar A, Knapik-Kordecka M, Warwas M. Markers of oxidative protein damage in plasma and urine of type 2 diabetic patients. Br J Biomed Sci. 2009;66(4):194-9.

Kalousova M, Zak A, Soukupova J, Stipek S, Malbohan IM, Zima T. [Advanced glycation and oxidation products in patients with atherosclerosis]. Cas Lek Cesk. 2005;144(6):385-9; discussion 9-90.

Lee DH, Jeon HK, Park HJ, Shin WS, Lee SW, Youn HJ, et al. Change in ischemia-modified albumin and its clinical significance during exercise stress testing. Circ J. 2010 Mar;74(3):484-9.

Abdilla N, Tormo MC, Fabia MJ, Chaves FJ, Saez G, Redon J. Impact of the components of metabolic syndrome on oxidative stress and enzymatic antioxidant activity in essential hypertension. J Hum Hypertens. 2007 Jan;21(1):68-75.

Matsuda M, Shimomura I. Increased oxidative stress in obesity: implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer. Obes Res Clin Pract. 2014 Sep-Oct;7(5):e330-41.

Hopps E, Caimi G. Protein oxidation in metabolic syndrome. Clin Invest Med.36(1):E1-8.

Zurawska-Plaksej E, Grzebyk E, Marciniak D, Szymanska-Chabowska A, Piwowar A. Oxidatively modified forms of albumin in patients with risk factors of metabolic syndrome. J Endocrinol Invest. 2014 Sep;37(9):819-27.

Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010 Sep 28;56(14):1113-32.

Yubero-Serrano EM, Delgado-Lista J, Pena-Orihuela P, Perez-Martinez P, Fuentes F, Marin C, et al. Oxidative stress is associated with the number of components of metabolic syndrome: LIPGENE study. Exp Mol Med. 2013;45:e28.

Demir B, Ozyazgan S, Korkmaz GG, Karakaya O, Aciksari G, Uygun T, et al. The relationship between ischemia modified albumin and oxidative stress parameters in patients with cardiac syndrome X. Clin Lab. 2014;59(11-12):1319-29.

Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011 Jun;32(11):1345-61.

Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005 Jun;54(6):1615-25.

Hiramatsu K, Arimori S. Increased superoxide

production by mononuclear cells of patients with hypertriglyceridemia and diabetes. Diabetes. 1988 Jun;37(6):832-7.

Dulak J, Polus M, Guevara I, Hartwich J, Wybranska I, Krzesz R, et al. Oxidized low density lipoprotein inhibits inducible nitric oxide synthase, GTP cyclohydrolase I and transforming growth factor beta gene expression in rat macrophages. J Physiol Pharmacol. 1999 Sep;50(3):429-41.

Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, et al. PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension. 2002 Dec;40(6):866-71.